Experimental study of early protective action of live influenza vaccine against heterologous influenza infection

Abstract

BACKGROUND: The live influenza vaccine is an effective means of combating influenza infection. It is characterized by ease of administration, cost-effectiveness, and rapid production, and it stimulates both systemic and local immune responses. This study investigates early protection against heterologous influenza infection within one week after immunization with the live influenza vaccine.

AIM: The aim of the study was to experimentally investigate the mechanisms of early protection against heterologous influenza infection following immunization with a live influenza vaccine.

MATERIALS AND METHODS: In in vitro experiments, we studied the production of type I interferons in a culture of monocyte-macrophage-derived cells using enzyme-linked immunosorbent assay. THP-1 cells were seeded at a concentration of 3 × 10⁶ cells/ml, and after 48 hours, the vaccine strain of the live influenza vaccine was added. Mice were immunized intranasally under light ether anesthesia with the vaccine virus A/17/South Africa/2013/01(H1N1)pdm09, obtained from the virus collection of the Virology Department of the Institute of Experimental Medicine, at a dose of 6.0 lg EID₅₀. Infection was performed on the 6th day after immunization with the virus A/Indonesia/5/2005(H5N1) IDCDC-RG2.

RESULTS: During the introduction of both the vaccine virus and the parental virus A/South Africa/3626/2013 (H1N1)pdm09 into THP-1 cell cultures, an increase in the production of early cytokines was observed. Immunization with the live influenza vaccine completely protected the mice from lethal infection with a heterologous influenza virus.

CONCLUSIONS: The obtained data may indicate the benefits of using the live influenza vaccine during the seasonal uptick of acute respiratory viral infections due to the stimulation of innate immune factors.

Keywords

live influenza vaccine / cytokines / influenza virus A

References

[1] Brisse M, Vrba SM, Kirk N, et al. Emerging concepts and technologies in vaccine development. Front Immunol. 2020;11:583077. doi: 10.3389/fimmu.2020.583077

[2] Brisse M., Vrba S.M., Kirk N., et al. Emerging concepts and technologies in vaccine development // Front Immunol. 2020. Vol. 11. P. 583077. doi: 10.3389/fimmu.2020.583077

[3] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi: 10.1016/S0140-6736(20)30925-9

[4] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 // Lancet. 2020. Vol. 396, N 10258. P. 1204–1222. doi: 10.1016/S0140-6736(20)30925-9

[5] Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207. doi: 10.1056/NEJMoa2001316

[6] Li Q., Guan X., Wu P., et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia // N Engl J Med. 2020. Vol. 382, N 13. P. 1199–1207. doi: 10.1056/NEJMoa2001316

[7] Lomidze MA, Gonik GG. Analysis of the epizootic situation in Russia on a particularly dangerous avian influenza infection. In: Socio-economic aspects of agricultural sector development. Krasnodar; 2021. P. 86–93. (In Russ.) EDN: SNTMOO

[8] Ломидзе М.А., Гоник Г.Г. Анализ эпизоотической ситуации в России по особо опасной инфекции птичьего гриппа. В кн.: Социально-экономические аспекты развития аграрного сектора. Краснодар, 2021. С. 86–93. EDN: SNTMOO

[9] Wong SS, Yuen KY. Avian influenza virus infections in humans. Chest. 2006;129(1):156–168. doi: 10.1378/chest.129.1.156

[10] Wong S.S., Yuen K.Y. Avian influenza virus infections in humans // Chest. 2006. Vol. 129, N 1. P. 156–168. doi: 10.1378/chest.129.1.156

[11] Bai L, Zhao Y, Dong J, et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 2021;31(4):395–403. doi: 10.1038/s41422-021-00473-1

[12] Bai L., Zhao Y., Dong J., et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity // Cell Res. 2021. Vol. 31, N 4. P. 395–403. doi: 10.1038/s41422-021-00473-1

[13] Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine. 2000;19(2–3):308–318. doi: 10.1016/S0264-410X(00)00153-5

[14] Rudenko L.G., Arden N.H., Grigorieva E., et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents // Vaccine. 2000. Vol. 19, N 2–3. P. 308–318. doi: 10.1016/S0264-410X(00)00153-5

[15] Grigor’eva EP, Rudenko LG, Desheva YuA, et al. Comparative assessment of the safety, immunogenic activity and prophylactic effectiveness of adult and pediatric versions of live influenza vaccine in schoolchildren aged 7-14 years. Voprosy virusologii. 2002;47(4):24–27. (In Russ.)

[16] Григорьева Е.П., Руденко Л.Г., Дешева Ю.А. и др. Сравнительная оценка безвредности, иммуногенной активности и профилактической эффективности взрослого и детского вариантов живой гриппозной вакцины у школьников 7–14 лет // Вопросы вирусологии. 2002. Т. 47, № 4. С. 24–27.

[17] Rathnasinghe R, Salvatore M, Zheng H, et al. Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. Sci Rep. 2021;11(1):22164. doi: 10.1038/s41598-021-01780-8

[18] Rathnasinghe R., Salvatore M., Zheng H., et al. Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1 // Sci Rep. 2021. Vol. 11, N 1. P. 22164. doi: 10.1038/s41598-021-01780-8

[19] Lee YJ, Lee JY, Jang YH, et al. Non-specific effect of vaccines: Immediate protection against respiratory syncytial virus infection by a live attenuated influenza vaccine. Front Microbiol. 2018;9:83. doi: 10.3389/fmicb.2018.00083

[20] Lee Y.J., Lee J.Y., Jang Y.H., et al. Non-specific effect of vaccines: Immediate protection against respiratory syncytial virus infection by a live attenuated influenza vaccine // Front Microbiol. 2018. Vol. 9. P. 83. doi: 10.3389/fmicb.2018.00083

[21] Rekstin AR, Desheva JA, Kiseleva IV, Isakova-Sivak IN. Early protection against influenza by pandemic live attenuated influenza vaccines. Medical Academic Journal. 2019;19(3):37–46. EDN: CLSYWW doi: 10.17816/MAJ19337-46

[22] Рекстин А.Р., Дешева Ю.А., Киселева И.В., Исакова-Сивак И.Н. Ранняя защита от гриппа с помощью пандемических живых гриппозных вакцин // Медицинский академический журнал. 2019. Т. 19, № 3. C. 37–46. EDN: CLSYWW doi: 10.17816/MAJ19337-46

[23] Desheva YA, Leontieva GF, Kramskaya TA, et al. Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection. Heliyon. 2019;5(2):e01154. doi: 10.1016/j.heliyon.2019.e01154

[24] Desheva Y.A., Leontieva G.F., Kramskaya T.A., et al. Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection // Heliyon. 2019. Vol. 5, N 2. P. e01154. doi: 10.1016/j.heliyon.2019.e01154

[25] Desheva YuA. Medical virology: educational and methodological recommendations for practical classes. Saint Petersburg: SpetsLit; 2019. 85 p. (In Russ.)

[26] Дешева Ю.А. Медицинская вирусология: учебно-методические рекомендации к практическим занятиям. Санкт-Петербург: СпецЛит, 2019. 85 с.

[27] Mironov AN, editor.Guidelines for conducting preclinical studies of medicinal products. Moscow: Grif i K; 2012. 944 p. (In Russ.) EDN: SDEWMP

[28] Руководство по проведению доклинических исследований лекарственных средств. Москва: Гриф и К, 2012. 944 с. EDN: SDEWMP

[29] Desheva Y, Leontieva G, Kramskaya T, et al. Live influenza vaccine provides early protection against homologous and heterologous influenza and may prevent post-influenza pneumococcal infections in mice. Microorganisms. 2022;10(6):1150. doi: 10.3390/microorganisms10061150

[30] Desheva Y., Leontieva G., Kramskaya T., et al. Live influenza vaccine provides early protection against homologous and heterologous influenza and may prevent post-influenza pneumococcal infections in mice // Microorganisms. 2022. Vol. 10, N 6. P. 1150. doi: 10.3390/microorganisms10061150

[31] Rubino G, Bulati M, Aiello A, et al. Sicilian centenarian offspring are more resistant to immune ageing. Aging Clin Exp Res. 2019;31:125–133. doi: 10.1007/s40520-018-0936-7

[32] Rubino G., Bulati M., Aiello A., et al. Sicilian centenarian offspring are more resistant to immune ageing // Aging Clin Exp Res. 2019. Vol. 31. P. 125–133. doi: 10.1007/s40520-018-0936-7

[33] Sridhar S, Begom S, Hoschler K, et al. Longevity and determinants of protective humoral immunity after pandemic influenza infection. Am J Respir Crit Care Med. 2015;191(3):325–332. doi: 10.1164/rccm.201410-1798OC

[34] Sridhar S., Begom S., Hoschler K., et al. Longevity and determinants of protective humoral immunity after pandemic influenza infection // Am J Respir Crit Care Med. 2015. Vol. 191, N 3. P. 325–332. doi: 10.1164/rccm.201410-1798OC

[35] Thomas M, Mani RS, Philip M, et al. Proinflammatory chemokines are major mediators of exuberant immune response associated with Influenza A (H1N1) pdm09 virus infection. J Med Virol. 2017;89(8):1373–1381. doi: 10.1002/jmv.24781

[36] Thomas M., Mani R.S., Philip M., et al. Proinflammatory chemokines are major mediators of exuberant immune response associated with Influenza A (H1N1) pdm09 virus infection // J Med Virol. 2017. Vol. 89, N 8. P. 1373–1381. doi: 10.1002/jmv.24781

[37] Garcia-Sastre A. Induction and evasion of type I interferon responses by influenza viruses. Virus Res. 2011;162(1–2):12–18. doi: 10.1016/j.virusres.2011.10.017

[38] Garcia-Sastre A. Induction and evasion of type I interferon responses by influenza viruses // Virus Res. 2011. Vol. 162, N 1–2. P. 12–18. doi: 10.1016/j.virusres.2011.10.017

[39] Osterlund P, Veckman V, Sirén J, et al. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol. 2005;79(15):9608–9617. doi: 10.1128/JVI.79.15.9608-9617.2005

[40] Osterlund P., Veckman V., Sirén J., et al. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells // J Virol. 2005. Vol. 79, N 15. P. 9608–9617. doi: 10.1128/JVI.79.15.9608-9617.2005

RIGHTS & PERMISSIONS

Eco-Vector